XML 23 R8.htm IDEA: XBRL DOCUMENT v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY (Unaudited) - USD ($)
$ in Millions
Total
Total Thermo Fisher Scientific Inc. Shareholders’ Equity
Common Stock
Capital in Excess of Par Value
Retained Earnings
Treasury Stock
Accumulated Other Comprehensive Income/(Loss)
Noncontrolling Interests
Beginning balance at Dec. 31, 2024 $ 120              
Redeemable Noncontrolling Interest [Roll Forward]                
Net income/(loss) 5              
Other comprehensive income/(loss) 3              
Ending balance at Mar. 29, 2025 128              
Common stock, beginning balance (in shares) at Dec. 31, 2024     444,000,000          
Beginning balance at Dec. 31, 2024 49,551 $ 49,584 $ 444 $ 17,962 $ 53,102 $ (19,226) $ (2,697) $ (33)
Treasury stock beginning balance (in shares) at Dec. 31, 2024           63,000,000    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of shares under stock plans 50 50   74   $ (24)    
Stock-based compensation 75 75   75        
Purchases of company common stock (in shares)           4,000,000    
Purchases of company common stock (2,000) (2,000)       $ (2,000)    
Dividends declared (163) (163)     (163)      
Net income/(loss) 1,507 1,507     1,507      
Other comprehensive income/(loss) 355 354         354 1
Contributions from (distributions to) noncontrolling interests (1)             (1)
Excise tax from stock repurchases (18) (18)       (18)    
Common stock, ending balance (in shares) at Mar. 29, 2025     444,000,000          
Ending balance at Mar. 29, 2025 49,357 49,390 $ 444 18,111 54,447 $ (21,269) (2,343) (33)
Treasury stock ending balance (in shares) at Mar. 29, 2025           67,000,000    
Beginning balance at Dec. 31, 2025 122              
Redeemable Noncontrolling Interest [Roll Forward]                
Net income/(loss) 4              
Other comprehensive income/(loss) (6)              
Ending balance at Mar. 28, 2026 121              
Common stock, beginning balance (in shares) at Dec. 31, 2025     445,000,000          
Beginning balance at Dec. 31, 2025 $ 53,415 53,407 $ 445 18,563 59,156 $ (22,309) (2,448) 7
Treasury stock beginning balance (in shares) at Dec. 31, 2025 68,938,831         69,000,000    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of shares under stock plans $ 44 44   66   $ (22)    
Stock-based compensation 83 83   83        
Purchases of company common stock (in shares)           5,000,000    
Purchases of company common stock (3,000) (3,000)       $ (3,000)    
Dividends declared (175) (175)     (175)      
Net income/(loss) 1,651 1,651     1,651      
Other comprehensive income/(loss) (49) (49)         (49)  
Contributions from (distributions to) noncontrolling interests (1)             (1)
Excise tax from stock repurchases (28) (28)       (28)    
Common stock, ending balance (in shares) at Mar. 28, 2026     445,000,000          
Ending balance at Mar. 28, 2026 $ 51,940 $ 51,934 $ 445 $ 18,713 $ 60,632 $ (25,360) $ (2,497) $ 7
Treasury stock ending balance (in shares) at Mar. 28, 2026 73,851,609         74,000,000